Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

NCT00467402
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 15, 2026, 6:11 AM EDT
Recruiting Not applicable Interventional

Stress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms

NCT07610928
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Mental Health (Depression)
Interventions
Stress Management and Resiliency Training with Qigong/Tai Chi, Healthy Living Program
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2026

NCT07685925
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neutralizing Interleukin (IL)-6

NCT07493317
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 3 Interventional Results available

Treatments for Depression: Drug Versus Psychotherapy

NCT00043550
View directory record Official record
Conditions
Depression
Interventions
Supportive Expressive Therapy, Sertraline, Pill Placebo, Venlafaxine
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 4 Interventional

A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care

NCT00939250
View directory record Official record
Conditions
Type 2 Diabetes, Major Depressive Disorder
Interventions
Diabetes and depression intervention, Diabetes intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 15, 2026, 6:11 AM EDT
Terminated Early Phase 1 Interventional

Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring

NCT01192685
View directory record Official record
Conditions
Depression
Interventions
Transcranial Magnetic Stimulation (TMS), near infrared spectroscopy (NIRS)
Procedure · Device
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03005 vs Pristiq

NCT03733574
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 15, 2026, 6:11 AM EDT
Terminated Phase 4 Interventional Results available

Antidepressant Response in Older Adults With Comorbid PTSD and MDD

NCT04697693
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Major Depressive Disorder
Interventions
Escitalopram, Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

NCT00183677
View directory record Official record
Conditions
Depression
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 15, 2026, 6:11 AM EDT
Recruiting Phase 2 Interventional

Mindfulness-based Psilocybin Therapy for PTSD

NCT07104916
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions
Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only
Combination Product
Lead sponsor
Anthony P King
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Results available

Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults

NCT01973283
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
Interventions
Antidepressant Medication
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 3 Interventional

Depression Study In Elderly Patients

NCT00067444
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
46
States / cities
Little Rock, Arkansas • Anaheim, California • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 15, 2026, 6:11 AM EDT
Not yet recruiting Not applicable Interventional

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

NCT07528157
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Personalized iTBS, Non-Personalized iTBS, Sham iTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Withdrawn Phase 4 Interventional

Creatine for Treatment of Depression Associated With Type 2 Diabetes

NCT03202095
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine Monohydrate
Drug
Lead sponsor
University of Utah
Other
Eligibility
20 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 15, 2026, 6:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Biomarkers for Depression

NCT01424111
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Healthy Control
Drug · Other
Lead sponsor
Wyss Institute at Harvard University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 15, 2026, 6:11 AM EDT
Withdrawn Not applicable Interventional

Auditory Stimulation for Insomnia and Depression

NCT07553364
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Insomnia
Interventions
Alpha phase-locked auditory stimulation, Sham Stimulation
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

NCT06775379
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Not applicable Interventional Results available

Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

NCT00612313
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

NCT03992846
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation in Major Depression

NCT03556124
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active - HD tDCS, Sham - HD tDCS, Active - Conventional tDCS, Sham - Conventional tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 15, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Results available

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

NCT01035073
View directory record Official record
Conditions
Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 15, 2026, 6:11 AM EDT